Cargando…

New drugs to treat tuberculosis

Tuberculosis (TB) has been a leading cause of death for more than a century. While effective therapies exist, treatment is long and cumbersome. Tuberculosis control is complicated by the overlapping problems created by global inadequacy of public health infrastructures, the interaction of the TB and...

Descripción completa

Detalles Bibliográficos
Autor principal: Swindells, Susan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Faculty of 1000 Ltd 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3370665/
https://www.ncbi.nlm.nih.gov/pubmed/22719795
http://dx.doi.org/10.3410/M4-12
_version_ 1782235145867100160
author Swindells, Susan
author_facet Swindells, Susan
author_sort Swindells, Susan
collection PubMed
description Tuberculosis (TB) has been a leading cause of death for more than a century. While effective therapies exist, treatment is long and cumbersome. Tuberculosis control is complicated by the overlapping problems created by global inadequacy of public health infrastructures, the interaction of the TB and human immunodeficiency virus epidemics, and the emergence of drug-resistant TB. After a long period of neglect, there is now significant progress in development of TB diagnostics and therapeutics. Focusing on treatment for active TB, we review the new pathways to TB regimen development, and the new and repurposed anti-TB agents in clinical development.
format Online
Article
Text
id pubmed-3370665
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Faculty of 1000 Ltd
record_format MEDLINE/PubMed
spelling pubmed-33706652012-06-20 New drugs to treat tuberculosis Swindells, Susan F1000 Med Rep Review Article Tuberculosis (TB) has been a leading cause of death for more than a century. While effective therapies exist, treatment is long and cumbersome. Tuberculosis control is complicated by the overlapping problems created by global inadequacy of public health infrastructures, the interaction of the TB and human immunodeficiency virus epidemics, and the emergence of drug-resistant TB. After a long period of neglect, there is now significant progress in development of TB diagnostics and therapeutics. Focusing on treatment for active TB, we review the new pathways to TB regimen development, and the new and repurposed anti-TB agents in clinical development. Faculty of 1000 Ltd 2012-06-01 /pmc/articles/PMC3370665/ /pubmed/22719795 http://dx.doi.org/10.3410/M4-12 Text en © 2012 Faculty of 1000 Ltd http://creativecommons.org/licenses/by-nc/3.0/legalcode This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. You may not use this work for commercial purposes
spellingShingle Review Article
Swindells, Susan
New drugs to treat tuberculosis
title New drugs to treat tuberculosis
title_full New drugs to treat tuberculosis
title_fullStr New drugs to treat tuberculosis
title_full_unstemmed New drugs to treat tuberculosis
title_short New drugs to treat tuberculosis
title_sort new drugs to treat tuberculosis
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3370665/
https://www.ncbi.nlm.nih.gov/pubmed/22719795
http://dx.doi.org/10.3410/M4-12
work_keys_str_mv AT swindellssusan newdrugstotreattuberculosis